Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


CapMan Life Science IV fund closes at EUR 54 million

CapMan Life Science IV fund held its final closing today at EUR 54 million. The fund invests in medical technology and service companies mainly in the Nordic countries.

A total of eight institutional investors joined CapMan Life Science IV, and of the investors two were new investors in CapMan funds. CapMan Plc’s own commitment to the fund is EUR 10 million.

“We are pleased with the fundraising outcome and especially happy for having been able to expand our life science investor base outside the Nordic countries and to welcome new investors to the fund. During CapMan Life Science IV’s fundraising period the investor appetite has mainly been directed at buyout funds and the investors’ venture allocations have been limited,” states Jerome Bouix, Partner and Head of Fundraising, IR and Communications.

CapMan Life Science IV is the largest life science fund managed by CapMan so far. Its investment focus is in medical technology and service companies mainly in the Nordic countries. CapMan Life Science IV has already made investments in three companies. Neoventa Medical AB is specialised in fetal monitoring in perinatal healthcare, ProstaLund AB manufactures devices for treatment of benign prostatic hyperplasia and QuickCool AB develops a new method for quick cooling of the brain to prevent brain damage. CapMan’s Life Science team has invested altogether in 18 companies and exited from nine of them. The team participates in the development of portfolio companies for example through Board work.

”The new fund has started investment operations very actively and the number of potential investment targets within the fund’s investment focus has remained at a good level both in terms of quantity and quality. Our team sees over 80% of the Nordic investment opportunities within the fund’s focus and a significant number of potential deals coming from the rest of Europe. In the next few years the fund will make investments in six to eight new companies,” says Jan Lundahl, Senior Partner and Head of CapMan Life Science.

The management fee of CapMan Life Science IV fund is in accordance with common practice in the industry. In connection with the establishment of the fund in March 2006, the Board of Directors of CapMan Plc decided that 50% of CapMan Life Science IV’s possible carried interest will be distributed to the members of the investment team responsible for the fund’s investment activities during its life cycle. A new fund starts to generate carried interest after the investors have regained their investment and an 8% preferred annual return. In venture funds this typically takes place towards the end of the funds’ 10 year life cycle.

For further information please contact:
Jan Lundahl, Senior Partner, Head of CapMan Life Science, tel. +46 8 545 854 75 or +46 708 56 19 53

Jerome Bouix, Partner, Fundraising, IR and Communications, tel. +358 9 6155 8358 or +358 40 820 8541

Jerome Bouix
Fundraising, IR and Communications

CapMan is one of the leading private equity investors in the Nordic countries and manages Nordic buyout, mezzanine, technology, life science and real estate funds with approximately EUR 3.0 billion in total capital. Each investment area has a dedicated team and altogether CapMan employs around 100 people in Helsinki, Stockholm, Copenhagen and Oslo. Established in 1989, CapMan has strong experience as a fund manager and as a partner for investors and entrepreneurs. To date CapMan has made over 150 Nordic investments and over 90 exits. The current portfolio encompasses over 60 companies with an aggregate turnover of approx. EUR 2.7 billion and aggregate personnel of 17,000 people. The latest investments are made in Finnish Novintel Oy, Danish ScanJour A/S, Swedish QuickCool AB and Norwegian InfoCare ASA. In addition, CapMan has invested in 27 real estate assets and exited from 22. The B shares of CapMan Plc are listed on the Main List of the Helsinki Stock<

Publisher Contact Information:

CapMan Capital Management Oy
+46 8 545 854 75

Company profile of CapMan Capital Management Oy
Past press releases of CapMan Capital Management Oy.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Oct 16€11.0MOther Biotechnology & Healthcare
Oct 16€6.3MBiotechnology
Oct 15€4.0MSecurity
Oct 15€25.0MBiotechnology
Oct 15€169.0MOther Communications
Oct 15€4.1MSmart cards

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.